2561.HK
Price:
$34.66
Market Cap:
$3.59B
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People's Republic of China, Hong Kong, and Taiwan. Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism. It has strategic collaboration agreements with Shanghai Pharmaceutical and the United...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2025-03-21
Stock Exchange
HKSE
Ticker
2561.HK
According to VISEN Pharmaceuticals’s latest financial reports and current stock price. The company's current ROE is -38.68%. This represents a change of 200.13% compared to the average of -12.89% of the last 4 quarters.
The mean historical ROE of VISEN Pharmaceuticals over the last ten years is -61.22%. The current -38.68% ROE has changed -36.82% with respect to the historical average. Over the past ten years (40 quarters), 2561.HK's ROE was at its highest in in the June 2024 quarter at 0%. The ROE was at its lowest in in the December 2024 quarter at -21.86%.
Average
-61.22%
Median
-63.85%
Minimum
-75.53%
Maximum
-44.28%
Discovering the peaks and valleys of VISEN Pharmaceuticals ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 44.20%
Maximum Annual ROE = -44.28%
Minimum Annual Increase = 0%
Minimum Annual ROE = -75.53%
| Year | ROE | Change |
|---|---|---|
| 2024 | -75.53% | 18.30% |
| 2023 | -63.85% | 44.20% |
The current ROE of VISEN Pharmaceuticals (2561.HK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-61.22%
5-year avg
-61.22%
10-year avg
-61.22%
VISEN Pharmaceuticals’s ROE is less than Hua Medicine (Shanghai) Ltd. (232.98%), greater than Peijia Medical Limited (-11.27%), greater than AIM Vaccine Co., Ltd. (-8.07%), less than China Resources Medical Holdings Company Limited (7.45%), less than Medtide Inc. (0%), less than TYK Medicines, Inc (153.33%), greater than Qyuns Therapeutics Co., Ltd. (-84.24%), less than Jacobson Pharma Corporation Limited (12.32%), less than Adicon Holdings Limited (0%), less than Modern Dental Group Limited (16.76%),
| Company | ROE | Market cap |
|---|---|---|
| 232.98% | $3.19B | |
| -11.27% | $3.86B | |
| -8.07% | $4.18B | |
| 7.45% | $4.17B | |
| 0% | $3.98B | |
| 153.33% | $5.29B | |
| -84.24% | $4.50B | |
| 12.32% | $2.49B | |
| 0% | $3.65B | |
| 16.76% | $4.93B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VISEN Pharmaceuticals using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like VISEN Pharmaceuticals or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is VISEN Pharmaceuticals's ROE?
How is the ROE calculated for VISEN Pharmaceuticals (2561.HK)?
What is the highest ROE for VISEN Pharmaceuticals (2561.HK)?
What is the 3-year average ROE for VISEN Pharmaceuticals (2561.HK)?
What is the 5-year average ROE for VISEN Pharmaceuticals (2561.HK)?
How does the current ROE for VISEN Pharmaceuticals (2561.HK) compare to its historical average?